Synaptic protein levels altered in vascular dementia

Neuropathology and Applied Neurobiology

Volumn 41, Issue 4, 2015, Pages 533-543

  Sinclair, Lindsey I ^a   Tayler, Hannah M ^b   Love, Seth ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Apolipoproteins E; DLG4 protein human; Drebrins; SNAP 25 protein human; Synaptophysin; Vascular dementia

Indexed keywords

DREBRIN; NEURON SPECIFIC ENOLASE; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; VASCULOTROPIN; DLG4 PROTEIN, HUMAN; DREBRINS; MEMBRANE PROTEIN; NEUROPEPTIDE; SIGNAL PEPTIDE; SNAP25 PROTEIN, HUMAN; SYP PROTEIN, HUMAN; VASCULOTROPIN A;

AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT; MULTIINFARCT DEMENTIA; PATHOGENESIS; PRIORITY JOURNAL; SIMULATION; SUPERIOR TEMPORAL GYRUS; SYNAPSE; TEMPORAL CORTEX; VERY ELDERLY; METABOLISM; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; DEMENTIA, VASCULAR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NEUROPEPTIDES; SYNAPSES; SYNAPTOPHYSIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TEMPORAL LOBE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929264571     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12215     Document Type: Article

References (63)

1. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672-2713
2. Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JCS, Jones B, Lyketsos C, Dulberg C. Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc 2004; 52: 195-204
3. Chui HC. Vascular cognitive impairment: today and tomorrow. Alzheimers Dement 2006; 2: 185-194
4. Grinberg LT, Heinsen H. Toward a pathological definition of vascular dementia. J Neurol Sci 2010; 299: 136-138
5. Jellinger K. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007; 113: 349-388
6. VICCCS. Vascular impairment of cognition classification consensus study. 2013; Available at: http://www.vicccs.info/ (last accessed 29 October 2013)
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 5th edn. Arlington, VA: American Psychiatric Association, 2013
8. World Health Organisation. ICD-10: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 10th edn. Geneva: World Health Organisation, 1992
9. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol 2003; 2: 89-98
10. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120: 287-296
11. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, Danni O, Parola M, Smith MA, Perry G, Tamagno E, Tabaton M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1α. J Neurochem 2009; 108: 1045-1056
12. Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Aβ generation by altering β- and γ-cleavage of APP. Neurobiol Aging 2009; 30: 1091-1098
13. Tanimukai H, Imaizumi K, Kudo T, Katayama T, Tsuda M, Takagi T, Tohyama M, Takeda M. Alzheimer-associated presenilin-1 gene is induced in gerbil hippocampus after transient ischemia. Mol Brain Res 1998; 54: 212-218
14. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao F-F, Xu H, Zhang Y-W. Hypoxia-inducible Factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-Amyloid generation. J Biol Chem 2007; 282: 10873-10880
15. Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y, Jieying L. Upregulation of BACE1 and β-Amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res 2009; 34: 1226-1235
16. Iadecola C. Cerebrovascular effects of amyloid-β peptides: mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol 2003; 23: 681-689
17. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 2001; 281: H2417-2424
18. Palmer JC, Tayler HM, Love S. Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease. J Alzheimers Dis 2013; 36: 577-587
19. Palmer JC, Barker R, Kehoe PG, Love S. Endothelin-1 is elevated in Alzheimer's disease and upregulated by Amyloid-β. J Alzheimers Dis 2012; 29: 853-861
20. Miners JS, Van Helmond Z, Raiker M, Love S, Kehoe PG. ACE variants and association with brain Aβ levels in Alzheimer's disease. Am J Transl Res 2011; 3: 73-80
21. Davies CA, Mann DMA, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-164
22. Masliah E, Hansen L, Albright T, Mallory M, Terry RD. Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease. Acta Neuropathol 1991; 81: 428-433
23. Chang RYK, Nouwens AS, Dodd PR, Etheridge N. The synaptic proteome in Alzheimer's disease. Alzheimers Dement 2013; 9: 499-511
24. Zhan S, Beyreuther K, Schmitt H. Synaptophysin immunoreactivity of the cortical neuropil in vascular dementia of Binswanger type compared with the dementia of Alzheimer type and nondemented controls. Dementia 1994; 5: 79-87
25. Zhan S, Beyreuther K, Schmitt H. Vascular dementia in Spatz-Lindenberg's disease (SLD): cortical synaptophysin immunoreactivity as compared with dementia of Alzheimer type and non-demented controls. Acta Neuropathol 1993; 86: 259-264
26. Uniprot, Consortium. UniProtKB. 2012; Available from: http://www.uniprot.org
27. Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38, 000 characteristic of presynaptic vesicles. Cell 1985; 41: 1017-1028
28. Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem Biophys Res Commun 1997; 236: 239-242
29. Love S, Siew LK, Dawbarn D, Wilcock GK, Ben-Shlomo Y, Allen SJ. Premorbid effects of APOE on synaptic proteins in human temporal neocortex. Neurobiol Aging 2006; 27: 797-803
30. Tannenberg RK, Scott HL, Tannenberg AEG, Dodd PR. Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE ε{lunate}4. Neurochem Int 2006; 49: 631-639
31. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 2006; 65: 592-601
32. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127-129
33. Sze C-I, Troncoso JC, Kawas C, Moution P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 933-944
34. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580
35. Greber S, Lubec G, Cairns N, Fountoulakis M. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease. Electrophoresis 1999; 20: 928-934
36. Furuya TK, Silva PNO, Payão SLM, Bertolucci PHF, Rasmussen LT, De Labio RW, Braga ILS, Chen ES, Turecki G, Mechawar N, Mill J, Smith MAC. Analysis of SNAP25 mRNA expression and promoter DNA methylation in brain areas of Alzheimer's Disease patients. Neuroscience 2012; 220: 41-46
37. Connelly SJ, Mukaetova-Ladinska EB, Abdul-All Z, Alves da Silva J, Brayne C, Honer WG, Mann DMA. Synaptic changes in frontotemporal lobar degeneration: correlation with MAPT haplotype and APOE genotype. Neuropathol Appl Neurobiol 2011; 37: 366-380
38. NCBI. Entrez gene. 2010. Available at: http://www.ncbi.nlm.nih.gov/gene/ ([last accessed 23 August 2010).
39. Woods GF, Oh WC, Boudewyn LC, Mikula SK, Zito K. Loss of PSD-95 enrichment is not a prerequisite for spine retraction. J Neurosci 2011; 31: 12129-12138
40. Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Aβ, and neurodegeneration in a prodromal stage of Alzheimer's disease. J Neurosci Res 2010; 88: 469-477
41. Proctor DT, Coulson EJ, Dodd PR. Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 2010; 21: 795-811
42. Julien C, Tremblay C, Bendjelloul F, Phivilay A, Coulombe M-A, Émond V, Calon F. Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J Neurosci Res 2008; 86: 2292-2302
43. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and down syndrome. Neurosci Lett 2002; 324: 209-212
44. Counts SE, He B, Nadeem M, Wuu J, Scheff SW, Mufson EJ. Hippocampal drebrin loss in mild cognitive impairment. Neurodegener Dis 2012; 10: 216-219
45. Licht T, Keshet E. Delineating multiple functions of VEGF-A in the adult brain. Cell Mol Life Sci 2013; 70: 1727-1737
46. Tarkowski E, Issa R, Sjögren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237-243
47. Plate KH. Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 1999; 58: 313-320
48. Olsson Y, Brun A, Englund E. Fundamental pathological lesions in vascular dementia. Acta Neurol Scand Suppl 1996; 168: 31-38
49. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404
50. American Psychiatric Association. Diagnostic and Statistical Manual of Diseases 4th edn. Arlington, VA: American Psychiatric Association., 2000. text revision
51. Barker R, Wellington D, Esiri MM, Love S. Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins. J Cereb Blood Flow Metab 2013; 33: 1050-1057
52. Ashby EL, Love S, Kehoe PG. Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. Neurobiol Aging 2012; 33: 1345-1355
53. Miners S, Moulding H, de Silva R, Love S. Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies. Brain Pathol 2014; 24: 334-343
54. Tayler H, Fraser T, Miners JS, Kehoe PG, Love S. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β. J Alzheimers Dis 2010; 4: 1363-1373
55. MRC, CFAS. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 357: 169-175
56. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes RG, Honer W, Harrington CR, Wischik CM. Staging of cytoskeletal and β-Amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 2000; 157: 623-636
57. Ivanov A, Esclapez M, Ferhat L. Role of drebrin A in dendritic spine plasticity and synaptic function: implications in neurological disorders. Commun Integr Biol 2009; 2: 268-270
58. Lee D, Aoki C. Presenilin conditional double knockout mice exhibit decreases in drebrin a at hippocampal CA1 synapses. Synapse 2012; 66: 870-879
59. Takahashi H, Mizui T, Shirao T. Down-regulation of drebrin A expression suppresses synaptic targeting of NMDA receptors in developing hippocampal neurones. J Neurochem 2006; 97: 110-115
60. Takahashi H, Sekino Y, Tanaka S, Mizui T, Kishi S, Shirao T. Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J Neurosci 2003; 23: 6586-6595
61. Kobayashi S, Shirao T, Sasaki T. Drebrin expression is increased in spinal motoneurons of rats after axotomy. Neurosci Lett 2001; 311: 165-168
62. Saruki N. The changes of central nervous synapses after transient cerebral ischemia. Masui 1995; 44: 1639-1647
63. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 2004; 101: 2173-2178